Journal of Clinical Oncology
Articles in this Issue
HealthTree survey as an identifier of venous thromboembolism risk mitigation targets in newly diagnosed multiple myeloma.
e19580 Background: Patients (pts) with newly diagnosed multiple myeloma (NDMM) are at significantly increased risk of veno...
Clinical utility of comprehensive molecular profiling in cholangiocarcinoma.
e16206 Background: Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary tract malignancies with distinct mo...
Ocular cancer and inpatient thrombotic phenotypes: Associations with retinal vascular occlusions and venous thromboembolism in the 2018-2022 National Inpatient Sample.
e23424 Background: Cancer-associated thrombosis is common, but ocular malignancy may have distinct local and systemic vasc...
Is the accelerator working? An updated empirical analysis of FDA accelerated approvals.
e23025 Background: Since 1992, accelerated approval (AA) has become the most common pathway for initial approval of cancer...
Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.
5565 Background: GIS is a key component of a companion diagnostic assay for determining homologous recombination deficienc...
Global validation of a brain cancer liquid biopsy.
2052 Background: Delayed diagnosis of brain cancer leads to approximately two-thirds of patients being identified only aft...
The Engage program for childhood cancer survivors: Results from a multidisciplinary, distance-delivered intervention.
1670 Background: As the growing number of childhood cancer survivors exceeds follow-up care capacity, scalable models to i...
Effect of smoking status on risk of mortality for patients with lung cancer treated with immunotherapy.
e20648 Background: Immune checkpoint inhibitors have become a mainstay of treatment for lung cancer. However, their effect...
Mortality involving breast cancer and chronic lower respiratory diseases among postmenopausal women in the United States: A CDC WONDER analysis (1999–2020).
e13785 Background: Breast cancer and chronic lower respiratory diseases (CLRD) are leading causes of mortality among postm...
Allogeneic hematopoietic cell transplantation following chimeric antigen receptor T-cell (CAR-T) therapy in B-cell acute lymphoblastic leukemia (B-ALL): A systematic review and meta-analysis.
e18577 Background: Chimeric antigen receptor T-cell (CAR-T) therapy induces high initial response rates in B-cell acute ly...
Prognostic impact of actionable driver alterations and efficacy of targeted therapy in lung squamous cell carcinoma: A large-scale nationwide genomic screening (LC-SCRUM-Asia).
8631 Background: Precision medicine based on multi-gene analysis improves prognosis and has established multigene analysis...
Age-stratified evaluation of subsequent primary malignancy risk in patients with primary Lynch syndrome–spectrum cancers.
10620 Background: Lynch syndrome spectrum cancers (LSSC) include several of the most common cancers in both men and women....
Real-world efficacy and safety of neoadjuvant TCHP in HER2-positive non-metastatic breast cancer in a government tertiary care center in India.
e12643 Background: Randomized trials support Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) in HER2-positive b...
National real-world adoption of 5-fraction breast radiotherapy in the United States (2020–2023).
590 Background: The landmark FAST-Forward trial demonstrated that ultra-hypofractionated whole-breast irradiation with 26...
Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
4192 Background: Spevatamig is an IgG1-based bispecific antibody targeting CLDN18.2 and CD47 with an optimized anti-CD47 a...
Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan/hepatic delivery system followed by tebentafusp in the treatment of metastatic uveal melanoma.
TPS9605 Background: Metastatic uveal melanoma (mUM) typically has a poor prognosis with limited treatment options. Tebenta...
Reducing ED utilization for oncologic neutropenic and non-neutropenic fever through an urgent care pathway: A quality improvement project.
e23282 Background: Emergency department (ED) utilization by oncology patients is high and wait times can be long, potentia...
Clinical characterization of patients with molecular glioblastoma.
e14074 Background: Glioblastoma (GBM) represents a highly aggressive type of WHO grade 4 intracranial tumor with a median...
Trends in hypofractionation, stereotactic body radiotherapy, metastatic radiotherapy utilization, and plan pricing at a tertiary cancer center: A plan-level analysis (2018–2024).
e23210 Background: Hypofractionation radiotherapy is supported by robust evidence across multiple disease sites, yet real-...
Morphological features of melanoma destruction under the influence of EGFR inhibitors: Gefitinib and a novel pyrimidine derivative.
e21539 Background: The global rise in cutaneous melanoma incidence necessitates the search for new therapeutic targets. Th...
The effectiveness of a multidisciplinary pain program in improving adherence to the use of aromatase inhibitors in breast cancer survivors.
12122 Background: Aromatase Inhibitors (AI) have become the standard of care to reduce breast cancer recurrence in hormone...
A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma.
TPS10057 Background: Ewing sarcoma (EWS) is an aggressive tumor of the bone and soft tissue primarily affecting adolescent...
Associations between circulating immunologic markers and HCC in individuals with chronic HCV infection.
e16271 Background: Although immunologic proteins have been associated with hepatocellular carcinoma (HCC) development, lit...
Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non–small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.
8572 Background: Immune checkpoint inhibitors (ICIs) have advanced the treatment paradigm for non-small cell lung cancer (...
Overall survival in patients with extensive stage small cell lung cancer treated with durvalumab instead of atezolizumab.
e20136 Background: Standard of care treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) includes...